BiotechTube

Blood sample

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thalassemia

Conditions

Thalassemia, Sickle Cell Disease, Myelodysplasia

Trial Timeline

Mar 1, 2012 → Mar 1, 2015

NCT ID
NCT01911871

About Blood sample

Blood sample is a pre-clinical stage product being developed by Novartis for Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01911871. Target conditions include Thalassemia, Sickle Cell Disease, Myelodysplasia.

What happened to similar drugs?

7 of 17 similar drugs in Thalassemia were approved

Approved (7) Terminated (2) Active (10)
✅DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
🔄deferasiroxNovartisPhase 3
🔄ICL670 + deferoxamineNovartisPhase 3
✅Zoledronic AcidNovartisApproved
✅DeferasiroxNovartisApproved
🔄DeferasiroxNovartisPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01911871Pre-clinicalCompleted

Competing Products

20 competing products in Thalassemia

See all competitors
ProductCompanyStageHype Score
LuspaterceptMerckPhase 2
35
luspaterceptMerckPhase 2
35
ACE-536MerckPhase 2
42
luspaterceptMerckPhase 2
35
DeferasiroxNovartisApproved
43
deferasirox + placeboNovartisPhase 2
35
Zoledronic acid + PlaceboNovartisPhase 2/3
34
deferasiroxNovartisApproved
35
deferasiroxNovartisPhase 3
40
ICL670 + deferoxamineNovartisPhase 3
40
ruxolitinibNovartisPhase 2
35
DeferasiroxNovartisPhase 2
35
Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT)NovartisPhase 2
35
Zoledronic AcidNovartisApproved
43
DeferasiroxNovartisPhase 2
27
DeferasiroxNovartisApproved
35
Deferasirox + Deferoxamine (DFO)NovartisPhase 2
27
DeferasiroxNovartisPhase 1
29
DeferasiroxNovartisPhase 3
40
DeferasiroxNovartisPhase 2
35